NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 715-720

  Gimeno, Eva ^a,b,c   Gómez, Miquel ^a   González, Juan Ramón ^c,d,e   Comín, Josep ^a   Alvarez Larrán, Alberto ^a,b   Sánchez González, Blanca ^a,b   Molina, Lluis ^a   Domingo Domenech, Eva ^f   Garcia Pallarols, Francesc ^a   Pedro, Carmen ^a,b   Abella, Eugenia ^a,b   Vilaplana, Carles ^g   de Sanjosé, Silvia ^f   Besses, Carlos ^a,b   Salar, Antonio ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g Laboratori de Referencia de Catalunya   (Spain)

Author keywords

Non Hodgkin lymphoma; NT proBNP; Prognostic factor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DEATH; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79955625070     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.018     Document Type: Article

References (39)

1. Coiffier B., Lepage E., Brière J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
2. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
3. Fisher R.I., LeBlanc M., Press O.W., Maloney D.G., Unger J.M., Miller T.P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447-8452.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994.
5. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
6. Thieblemont C., Coiffier B. Lymphoma in older patients. J Clin Oncol 2007, 25:1916-1923.
7. Cohen H.J. Cancer and functional status in the elderly. Cancer 1997, 80:1883-1886.
8. Malauguarnera M., Di Mauro S., Laurino A., Motta M., Di Fazio I., Maugeri D. The comorbidities of elderly oncologic patients. Arch Gerontol Geriatr 2000, 30:237-244.
9. Sundararajana V., Hendersona T., Perrya C., Muggivana A., Quanb H., Ghalib W.A. New ICD-10 version of the Charlson Comorbidity Index predicted in-hospital mortality. J Clin Epidemiol 2004, 57:1288-1294.
10. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., Gams R.A. Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer. J Clin Oncol 1997, 15:1318-1332.
11. Martino R., Perea G., Caballero M.D., Mateos M.V., Ribera J.M., de Oteyza J.P., Arranz R., Terol M.J., Sierra J., San Miguel J.F. Cyclophosphamide, pegylated liposomal doxorrubicin (Caelix), vincristine and prednisone (CCOP) in elderly patients with diffuse large-B-cell lymphoma: results from a prospective phase II study. Haematologica 2002, 87:822-827.
12. Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010, 53:121-129.
13. Monsuez J.J., Charniot J.C., Vignat N., et al. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010, 144:3-15.
14. Daniels L.B., Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 2007, 50:2357-2368.
15. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
16. Moe G.W., Howlett J., Januzzi J.L., Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVECHF study. Circulation 2007, 115:3103-3110.
17. James S.K., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003, 108:275-281.
18. Omland T., Sabatine M.S., Jablonski K.A., et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol 2007, 50:205-214.
19. Machado R.F., Anthi A., Steinberg M.H., et al. N-Terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006, 296:310-318.
20. Fijalkowska A., Kurzyna M., Torbicki A., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006, 129:1313-1321.
21. von Haehling S., Jankowska E., Morgenthaler N., et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007, 50:1973-1980.
22. Knight E.L., Kiely D.K., Fish L.C., et al. Atrial natriuretic peptide level contributes to a model of future mortality in the oldest old. J Am Geriatr Soc 1998, 46:453-457.
23. Dispenzieri A., Kyle R.A., Gertz M.A., et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003, 361:1787-1789.
24. Dispenzieri A., Gertz M.A., Kyle R.A., et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood 2004, 104:181-187.
25. Gardin J.M., Adams D.B., Douglas P.S., et al. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr 2002, 15:275-290.
26. Wu A.H., Smith A., Wieczorek S., et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003, 92:628-631.
27. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
28. Hosnijeh F.S., Krop E., Scoccianti, et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2010, 19:1577-1584.
29. Aldinucci D., Gloghini A., Pinto A., et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221:248-263.
30. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994, 90:195-203.
31. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
32. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
33. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
34. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
35. Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007, 25:1824-1831.
36. Maas H.A., Janssen-Heijnen M.L., Olde Rikkert M.G., Machteld Wymenga A.N. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 2007, 43:2161-2169.
37. Charlson M.E., Pompei P., Ales K.L., AlacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
38. Evans L.S., Hancock B.W. Non-Hodgkin lymphoma. Lancet 2003, 362:139-146.
39. Gimeno E, Sánchez-González B, Alvarez-Larrán A, et al. Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leuk Res 2010, doi:10.1016/j.leukres.2010.07.024.